99548-52-4

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(5-bromo-2-nitrophenylamino)propionic acid is used as a reagent for the synthesis of various pharmaceuticals and organic compounds. Its chemical structure, which includes both nitro and bromo groups, makes it a versatile building block in the preparation of bioactive molecules, contributing to the development of new drugs with potential therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, 2-(5-bromo-2-nitrophenylamino)propionic acid is utilized for its reactivity in various chemical reactions such as nucleophilic substitutions and coupling reactions. Its presence of functional groups allows for the formation of new chemical entities, expanding the scope of organic synthesis and the creation of novel compounds with specific properties.
Used in Bioactive Molecule Preparation:
2-(5-bromo-2-nitrophenylamino)propionic acid is also used as a precursor in the preparation of bioactive molecules. Its unique structure can confer biological activity to the resulting compounds, making it a valuable component in the synthesis of molecules with potential applications in medicine, agriculture, and other industries where bioactive substances are required.

Upstream product

• 51686-78-3 2,4-dibromonitrobenzene 
• 302-72-7 rac-Ala-OH 
• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 56-41-7 L-alanin 

Downstream Products

• 24463-25-0 6-bromo-3-methyl-3,4-dihydro-1H-quinoxalin-2-one 
• 1417408-91-3 7-bromo-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-40-0 1-(2-chlorophenyl)-7-ethynyl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-41-1 1-(2-chlorophenyl)-4-methyl-7-trimethylsilanylethynyl-[1,2,4]triazolo[4,3-a]quinoxaline 
• 1427029-12-6 2-(5-bromo-2-nitrophenylamino)propionic acid methyl ester 

Relevant academic research and scientific papers

TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS

The present invention is directed to triazolopyrazine compounds of Formula (I). Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds as therapeutic agents treating neurological and psychiatric disorders.

Benzimidazolones and analogues

The present invention provides compounds and pharmaceutical formulations useful as progesterone receptor agonists and antagonists and having the general formula: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R5are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alknyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alknyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl, C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromatic ring containing 1 or 2 substituents; Q is O, S, NR8, or CR9R10; or a pharmaceutically acceptable salt thereof. The invention also includes methods of contraception and methods of treating or preventing maladies associated with the progesterone receptor.

Combination therapies using benzimidazolones

This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein: A is O, S, or NR4; B is a bond between A and C═Q, or the moiety CR5R6; R4, R5, R6are independently selected from H or optionally substituted C1to C6alkyl, C2to C6alkenyl, C2to C6alkynyl, C3to C8cycloalkyl, substituted C3to C8cycloalkyl, aryl, or heterocyclic groups, or cyclic alkyl constructed by fusing R4and R5to from a 5 to 7 membered ring; R1is selected from H, OH, NH2, C1to C6alkyl, substituted C1to C6alkyl, C3to C6alkenyl, substituted C1to C6alkenyl, alkynyl, substituted alkynyl, —COH, or optionally substituted —CO(C1to C3alkyl), —CO(aryl), —CO(C1to C3alkoxy), or —CO(C1to C3aminoalkyl) groups; R2is selected from H, halogen, CN, NO2, or optionally substituted C1to C6alkyl C1to C6alkoxy, or C1to C6aminoalkyl groups; R3is selected from a trisubstituted benzene ring; or a 5- or 6-membered heteroaromnatic ring containing 1 or 2 substituents; or a pharmaceutically acceptable salt thereof, in combination with a progestational agent, an estrogen, or both or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate. These combinations may also be used to in methods of contraception, to stimulate food intake or for minimization of side effects or cyclic menstrual bleeding.